search
Back to results

Analysis of Cytokine Expression Pattern in Systemic Sclerosis (SCLEROKINE)

Primary Purpose

Systemic Sclerosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Skin biopsies
Sponsored by
Poitiers University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Systemic Sclerosis focused on measuring cytokine, skin inflammation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 year-old
  • Diagnosis of systemic sclerosis according to ACR/EURAL 2013 criteria.
  • Skin sclerosis reaching an area over finger bases of hands and feet
  • Free subject, without neither guardianship, wardship nor subordination
  • Patient with Social Security
  • Informed and signed consent by the patient after clear and loyal information on the study

Exclusion Criteria:

  • Age < 18 year-old
  • Patients that do not fit the ACR/EURAL 2013 criteria
  • Patients under immunosuppressive treatment
  • Sclerosis limited to fingers of hands and feets.
  • Patient without Social Security
  • Pregnant and nursing women

Sites / Locations

  • CHU de Poitiers

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sclerodermic patients

Arm Description

Sclerodermic patients presenting cutaneous fibrosis

Outcomes

Primary Outcome Measures

Skin IL-34 mRNA expression levels
Skin IL-34 mRNA expression levels (expressed in % of relative expression of GAPDH) in systemic sclerosis patients by comparison with healthy subjects. Skin biopsies are collected at D0 for SSc patients (inclusion day)

Secondary Outcome Measures

Immunostainings against IL-34 and other cytokines on skin sections
Immunostainings against IL-34 and other cytokines on skin sections from systemic sclerosis patients versus healthy skins
Protein expression levels of IL-34 and other cytokines by ELISA
Protein expression levels of IL-34 and other cytokines by ELISA (quantitative study) in plasma and lysates of skin biopsies from systemic sclerosis patients versus
Skin IL-34 mRNA expression levels of other cytokines
Skin IL-34 mRNA expression levels of other cytokines in patients with systemic sclerosis compared to healthy patients.

Full Information

First Posted
May 15, 2018
Last Updated
April 20, 2020
Sponsor
Poitiers University Hospital
Collaborators
University of Poitiers
search

1. Study Identification

Unique Protocol Identification Number
NCT03537105
Brief Title
Analysis of Cytokine Expression Pattern in Systemic Sclerosis
Acronym
SCLEROKINE
Official Title
Analysis of Cytokine Expression Pattern in Systemic Sclerosis: Study of the Role of Interleukine-34
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Completed
Study Start Date
July 12, 2018 (Actual)
Primary Completion Date
September 4, 2019 (Actual)
Study Completion Date
September 4, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Poitiers University Hospital
Collaborators
University of Poitiers

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
By contrast to other proinflammatory cytokines which are found up-regulated in the skin of patients with psoriasis, atopic dermatitis or systemic sclerosis, IL-34 is the only cytokine that undergoes down-regulation. This finding is interesting regarding the description of IL-34 as an immunosuppressive cytokine. In this study, the expression and the role of interleukin-34 (IL-34) will be investigated in the physiopathology of systemic sclerosis.
Detailed Description
The mechanisms involved in the physiopathology of systemic sclerosis (SSc) are not fully understood, particularly the pattern of cytokine expression in the skin of SSc patients. These cytokines are known to play a central role in the regulation of numerous inflammatory diseases and, among them, IL-34 is the only cytokine which has been found to be down-regulated in other skin inflammatory disorders such psoriasis or atopic dermatitis. IL-34 has been described as an immunosuppressive cytokine, and our preliminary results show that IL-34 is active on fibroblasts, a key cell that undergoes dysfunction in SSc. Thus, we are willing to explore its expression profile in the skin of SSc patients and its potential role in the physiopathology of the disease. For this study, we will analyze IL-34 mRNA levels in the skin and the plasma of SSc patients by comparison to healthy patients. Thirty patients will be included in the Internal Medicine Unit of the CHU de Poitiers during a single visit, in the frame of their medical follow-up, to collect two skin biopsies and 5 ml of blood after obtaining their informed consent. The expression of IL-34 will also be investigated at the protein level by immunostaining on skin sections and by ELISA (skin protein lysates and plasma). Moreover, the expression of other proinflammatory cytokines will be investigated both at the mRNA and protein levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Sclerosis
Keywords
cytokine, skin inflammation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Sclerodermic patients
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sclerodermic patients
Arm Type
Experimental
Arm Description
Sclerodermic patients presenting cutaneous fibrosis
Intervention Type
Procedure
Intervention Name(s)
Skin biopsies
Other Intervention Name(s)
Serum collection
Intervention Description
Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
Primary Outcome Measure Information:
Title
Skin IL-34 mRNA expression levels
Description
Skin IL-34 mRNA expression levels (expressed in % of relative expression of GAPDH) in systemic sclerosis patients by comparison with healthy subjects. Skin biopsies are collected at D0 for SSc patients (inclusion day)
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Immunostainings against IL-34 and other cytokines on skin sections
Description
Immunostainings against IL-34 and other cytokines on skin sections from systemic sclerosis patients versus healthy skins
Time Frame
1 day
Title
Protein expression levels of IL-34 and other cytokines by ELISA
Description
Protein expression levels of IL-34 and other cytokines by ELISA (quantitative study) in plasma and lysates of skin biopsies from systemic sclerosis patients versus
Time Frame
1 day
Title
Skin IL-34 mRNA expression levels of other cytokines
Description
Skin IL-34 mRNA expression levels of other cytokines in patients with systemic sclerosis compared to healthy patients.
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 year-old Diagnosis of systemic sclerosis according to ACR/EURAL 2013 criteria. Skin sclerosis reaching an area over finger bases of hands and feet Free subject, without neither guardianship, wardship nor subordination Patient with Social Security Informed and signed consent by the patient after clear and loyal information on the study Exclusion Criteria: Age < 18 year-old Patients that do not fit the ACR/EURAL 2013 criteria Patients under immunosuppressive treatment Sclerosis limited to fingers of hands and feets. Patient without Social Security Pregnant and nursing women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-François Jégou, PhD
Organizational Affiliation
University of Poitiers
Official's Role
Study Director
Facility Information:
Facility Name
CHU de Poitiers
City
Poitiers
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Analysis of Cytokine Expression Pattern in Systemic Sclerosis

We'll reach out to this number within 24 hrs